FEIBA case studies during ITI

FEIBA prophylaxis during ITI has been shown to provide benefits to haemophilia patients with inhibitors. Explore the real-life case studies outlined on this page to see the outcome of FEIBA prophylaxis:

In a case series of six patients*, three underwent ITI with FEIBA prophylaxis1

In another case series of five patients, two underwent ITI with FEIBA prophylaxis

References

  1. 1. Valentino LA. The benefits of prophylactic treatment with APCC in patients with haemophilia and high-titre inhibitors: a retrospective case series. Haemophilia. 2009: 15:733-742.
  2. 2. Leissinger CA, Becton DL, Ewing NP, Valentino LA. Prophylactic treatment with activated prothrombin complex concentrate (FEIBA) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors. Haemophilia. 2007:1-7.

Proven efficacy

Discover the efficacy of FEIBA in both on-demand and prophylaxis treatment. Read more

Dosing FEIBA

Learn how to dose FEIBA. Read more

Prophylaxis

Learn how FEIBA prophylaxis may help protect your patients against bleeds. Read more